Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (271-280 of 457) with videos related to

Pageof 46
Sort By:
Blood|January 13, 2016
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupsMarlise R Luskin, Ju-Whei Lee, Hugo F Fernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant ErythropoietinAlan F List, Zhuoxin Sun, Amit Verma, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemiaMichael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2010
Second unrelated donor hematopoietic cell transplantation for primary graft failureJeffrey Schriber, Manza-A Agovi, Vincent Ho, et al.
Blood|March 22, 2014
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targetsMichelle K Gleason, Julie A Ross, Erica D Warlick, et al.
Haematologica|February 16, 2023
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survivalMaymona G Abdelmagid, Aref Al-Kali, Kebede H Begna, et al.
Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2010
Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adultsWillis H Navarro, Manza-A Agovi, Brent R Logan, et al.
Leukemia & Lymphoma|January 21, 2003
Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activatorMark R Litzow, Panagiotis D Repoussis, Georgene Schroeder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 28, 2012
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilizationIvana N M Micallef, Shirshendu Sinha, Dennis A Gastineau, et al.
Pageof 46

Showing results (271-280 of 457) with videos related to

Sort By:
Pageof 46
Blood|January 13, 2016
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupsMarlise R Luskin, Ju-Whei Lee, Hugo F Fernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant ErythropoietinAlan F List, Zhuoxin Sun, Amit Verma, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemiaMichael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2010
Second unrelated donor hematopoietic cell transplantation for primary graft failureJeffrey Schriber, Manza-A Agovi, Vincent Ho, et al.
Blood|March 22, 2014
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targetsMichelle K Gleason, Julie A Ross, Erica D Warlick, et al.
Haematologica|February 16, 2023
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survivalMaymona G Abdelmagid, Aref Al-Kali, Kebede H Begna, et al.
Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2010
Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adultsWillis H Navarro, Manza-A Agovi, Brent R Logan, et al.
Leukemia & Lymphoma|January 21, 2003
Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activatorMark R Litzow, Panagiotis D Repoussis, Georgene Schroeder, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 28, 2012
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilizationIvana N M Micallef, Shirshendu Sinha, Dennis A Gastineau, et al.
Pageof 46